Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec;57(1):2527352.
doi: 10.1080/07853890.2025.2527352. Epub 2025 Jul 11.

Rationale and design of the GLADE study: a randomized, multicenter, double-blind, placebo-controlled trial evaluating the safety and efficacy of gestrinone subdermal bioabsorbable pellet in endometriosis-related pelvic pain

André Malavasi  1   2 , Camilla Moreira Ribeiro  2 , Leandro Barile Agati  2 , Agnaldo Silva Filho  3 , Charles Berger  4 , Eduardo Schor  5 , Ana Comin  6 , Eduardo José Bezerra Neto  7 , Taís Helena de Oliveira  8 , Polyana Raposo Caldas  8 , Francisco Lopes  9 , Nathalia Westphalen  9 , Francisleny Vieira  2 , Eduardo Augusto Rabelo Socca  2 , Daniele Komar  2 , Eduardo Ramacciotti  2   10
Affiliations

Rationale and design of the GLADE study: a randomized, multicenter, double-blind, placebo-controlled trial evaluating the safety and efficacy of gestrinone subdermal bioabsorbable pellet in endometriosis-related pelvic pain

André Malavasi et al. Ann Med. 2025 Dec.

Abstract

Background: Pelvic pain secondary to endometriosis is a disabling condition. There are multiple treatments available, with variable endpoints. No prospective controlled studies were carried out evaluating subdermal pellets of gestrinone in this population.

Methods: One hundred participants with documented deep infiltrative endometriosis who underwent surgery without satisfactory response will be randomly assigned (1:1) to either gestrinone 85 mg subdermal bioabsorbable pellets or placebo. Both arms will receive levonorgestrel-releasing intrauterine system (LNG-IUS 12). The treatment duration will be 6 months, with baseline, 3 months and 6 months clinical visits. The primary endpoint is a combination of serious adverse events (SAEs) accumulated within 6 months of insertion of the gestrinone or placebo pellet and collected through spontaneous reports and clinical findings. They include death, threat or risk to life, need for hospitalization, prolongation of pre-existing hospitalization, permanent disability or damage, congenital anomaly; or significant medical occurrences such as venous thromboembolism. The primary safety outcome will be the percentage of patients who do not experience SAEs 6 months after randomization. Androgenization, changes in laboratory exams and in pelvic pain intensity as well as quality of life (SF-36 and EHP-30 questionnaires) will be further evaluated. Daily data on uterine bleeding patterns and the use of pain relief medication will be remotely collected using an App. Pharmacokinetics profile of gestrinone pellet will be characterized.

Conclusion: This is the first multicenter randomized controlled trial to evaluate the safety, tolerability and pharmacokinetics profile of subdermal gestrinone pellets and might inform clinical practice for treating these patients.

Administrative information: GLADE trial is registered at ClinicalTrials.gov (NCT05570786). This is an investigator-initiated research supported by Biòs Farmacêutica.

Keywords: Endometriosis; R-2323; gestrinone; pelvic pain; subcutaneous pellet.

PubMed Disclaimer

Conflict of interest statement

ER reports grants and consulting fees from Bayer and Pfizer, the Brazilian Ministry of Science and Technology, and personal fees from Aché Pharma, Novartis, and Daiichi-Sankyo outside the submitted work. LBA reports grants from Bayer, Pfizer, and the Brazilian Ministry of Science and Technology. All other authors declare there are no competing interests to declare, and no relevant financial or non-financial competing interests to report.

Figures

Figure 1.
Figure 1.
Protocol innovations.
Figure 2.
Figure 2.
Study design.
See this image and copyright information in PMC

References

    1. Ahangari A. Prevalence of chronic pelvic pain among women: an updated review. Pain Physician. 2014;17(2):E141–7. doi: 10.36076/ppj.2014/17/E141. - DOI - PubMed
    1. Ayorinde AA, Macfarlane GJ, Saraswat L, et al. Chronic pelvic pain in women: an epidemiological perspective. Womens Health (Lond). 2015;11(6):851–864. doi: 10.2217/whe.15.30. - DOI - PubMed
    1. Zondervan KT, Becker CM, Koga K, et al. Endometriosis. Nat Rev Dis Primers. 2018;4(1):9. doi: 10.1038/s41572-018-0008-5. - DOI - PubMed
    1. Kalaitzopoulos DR, Samartzis N, Kolovos GN, et al. Treatment of endometriosis: a review with comparison of 8 guidelines. BMC Womens Health. 2021;21(1):397. doi: 10.1186/s12905-021-01545-5. - DOI - PMC - PubMed
    1. Johnson NP, Hummelshoj L, World Endometriosis Society Montpellier C . Consensus on current management of endometriosis. Hum Reprod. 2013;28(6):1552–1568. doi: 10.1093/humrep/det050. - DOI - PubMed

Publication types

MeSH terms

Associated data